Nicola Hanania, MD
Pulmonary Disease · Houston, TXNPI 1851471114
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 38.4% of the total. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 573 payments — averaging $2314.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$509K
- Sanofi$393K
- Regeneron Healthcare Solutions, Inc.$106K
- AstraZeneca$66K
- GSK$66K
- Astrazeneca AB$25K
- plus $161K from 23 others
Across 342 payments — averaging $2894.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$278K
- AstraZeneca$176K
- Sanofi US Services Inc.$141K
- GSK$102K
- Boehringer Ingelheim$94K
- Sanofi$41K
- plus $158K from 10 others
What the payments were for
- Consulting fees$478,13436%
- Speaking & faculty fees$658,73850%
- Grants$3,8990%
- Travel & lodging$170,25113%
- Food & beverage$15,1801%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 72 | $509,317 |
| Sanofi | 136 | $393,495 |
| Regeneron Healthcare Solutions, Inc. | 86 | $106,422 |
| AstraZeneca | 77 | $65,752 |
| GSK | 53 | $65,658 |
| Astrazeneca AB | 18 | $24,757 |
| Astrazeneca UK Limited | 14 | $18,821 |
| Teva Pharmaceuticals USA, Inc. | 3 | $18,325 |
| Regeneron | 8 | $18,120 |
| Mylan Specialty L.p. | 28 | $17,239 |
| F. Hoffmann-la Roche AG | 12 | $15,721 |
| Genentech USA, Inc. | 16 | $13,576 |
| Sanofi US Services Inc. | 4 | $13,363 |
| Chiesi USA, Inc. | 10 | $12,323 |
| Boehringer Ingelheim | 9 | $10,780 |
| Genentech, Inc. | 7 | $7,053 |
| Novartis Pharma AG | 3 | $3,773 |
| Amgen | 3 | $3,316 |
| Novartis | 2 | $3,216 |
| Pfizer | 1 | $2,500 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,200 |
| Mylan Inc. | 2 | $824 |
| Dermira, Inc. | 1 | $595 |
| Merck | 2 | $43 |
| Verona Pharma, Inc. | 1 | $31 |
| BD | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$796,543
- XOLAIR$25,758
- Yupelri$17,468
- FASENRA$17,338
- AirDuo Digihaler$16,375
- BEVESPI AEROSPHERE$12,315
- NUCALA$11,731
- STIOLTO RESPIMAT$8,917
- AIRSUPRA$6,488
- TRELEGY ELLIPTA$3,900
- IGE025A_XOLAIR _RESPIRATORY$3,759
- TEZSPIRE$3,758
- SYMBICORT$3,222
- BREZTRI$3,104
- Non-Covered Product$2,643
- BREZTRI AEROSPHERE$2,148
- ProAir Digihaler$1,950
- SPIRIVA$1,600
- PULMICORT RESPULES$1,297
- Tavalisse$1,200
How this compares
$1,326,301 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $140,442 |
| Dupixent PenDupilumab | 23 | $87,257 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $33,481 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,720 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,322 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $1,494 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,406 |
| Ventolin HfaAlbuterol Sulfate | 13 | $1,301 |
| Fluticasone Propionate | 29 | $356 |
| Montelukast Sodium | 23 | $252 |
| Prednisone | 22 | $167 |
| Pantoprazole Sodium | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $65,658 | $33,48144 claims |
| AstraZenecaSymbicort | $65,752 | $2,72011 claims |
| Mylan Inc.Wixela Inhub | $824 | $1,49415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Sandeep SahayHouston$378K
- Zeenat SafdarHouston$291K
- Howard HuangHouston$194K
- Brandy McKelvyHouston$168K
- Alexander StadnykHouston$158K
- Lisa KopasHouston$120K
- Sandeep GuptaHouston$118K
- Roberto CasalHouston$113K
- Dileep PuppalaHouston$108K
- Phuongdung NguyenHouston$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.